Generate Biomedicines, Inc.

Based in Massachusetts, US, and founded in 2018 by Molly Gibson (Co‑Founder); Gevorg Grigoryan (Co‑Founder & CTO); Noubar Afeyan (Founder & CEO), Generate Biomedicines, Inc. , formerly known as Flagship VL56, Inc. , operates as a therapeutics company that offers solutions for drug discovery and development. In February 2026, Generate Biomedicines, Inc.

 raised USD 400 million in an IPO, selling 25 million shares at USD 16 apiece, at Nasdaq, under the ticker "GENB". From this deal the company plans to increase their visibility in the marketplace and obtain additional capital. They may also use a portion of the net proceeds to in-license, acquire or invest in complementary businesses or technologies to continue to build our pipeline, research and development capabilities and our intellectual property position.   The company offers a biomedicine platform that can produce new medications on demand across a wide range of biologic modalities, including short peptides, complicated antibodies, enzymes, cytokines, and protein compositions that have yet to be identified.

The company uses machine learning technology for the identification and validation of targets and treatments, as well as the specificity of target engagement by produced proteins and the cost of identifying and producing clinical candidates. Generate Biomedicines earns revenue through strategic partnerships with pharma companies, licensing its AI-driven Generative Biology™ platform, and advancing proprietary therapeutics into clinical trials.